Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP63: Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study.ECCO'24 Stockholm
Year: 2024
Authors: Jansson, Sabine
DOP64: Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trialECCO'24 Stockholm
Year: 2024
Authors: Raine, Timothy
DOP65: Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trialECCO'24 Stockholm
Year: 2024
Authors: Amiot, Aurelien
DOP66: INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulasECCO'24 Stockholm
Year: 2024
Authors: Fathallah, Nadia
DOP67: MB310: From Clinical FMT to a Phase 1 Study with a Defined, Orally Administered Live Bacterial Therapeutic for Mild Moderate Ulcerative ColitisECCO'24 Stockholm
Year: 2024
Authors: Carter, Ron
DOP68: Natural history of isolated Crohn's Disease perianal fistulaECCO'24 Stockholm
Year: 2024
Authors: Wong, Serre-Yu
DOP69: Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker studyECCO'24 Stockholm
Year: 2024
Authors: Gacesa, Ranko
DOP70: Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) SurveyECCO'24 Stockholm
Year: 2024
Authors: Dubinsky, Marla C
DOP71: Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment doseECCO'24 Stockholm
Year: 2024
Authors: Sands, Bruce E
DOP72: Pregnancy for IBD-patients with an enterostomy is feasible but is associated with complicationsECCO'24 Stockholm
Year: 2024
Authors: Bouwknegt, Dianne G.
DOP73: Early biological use in a Belgian, prospective inception cohort of patients with Inflammatory Bowel Disease: the PANTHER cohortECCO'24 Stockholm
Year: 2024
Authors: Verstockt, Sare
DOP74: Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES studyECCO'24 Stockholm
Year: 2024
Authors: Chaparro, María
DOP75: Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDAECCO'24 Stockholm
Year: 2024
Authors: Rubín De Célix, Cristina
DOP76: Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studiesECCO'24 Stockholm
Year: 2024
Authors: Tinoco da Silva Torres, Joana
DOP77: Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case seriesECCO'24 Stockholm
Year: 2024
Authors: Pronk, Annelies
DOP78: Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North studyECCO'24 Stockholm
Year: 2024
Authors: Schreiber, Stefan Wolfgang
DOP79: Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohortECCO'24 Stockholm
Year: 2024
Authors: Verstockt, Bram
DOP80: Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO RegistryECCO'24 Stockholm
Year: 2024
Authors: Chaparro, María
DOP81: Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: Results from a Phase 1 healthy volunteer clinical trialECCO'24 Stockholm
Year: 2024
Authors: Sibley, Cailin
DOP83: Intestinal epithelium-specific deletion of the Aryl hydrocarbon Receptor (AhR) reduces intestinal Tight Junction permeability thereby hindering homeostatic antigen sampling and tolerogenic immune responses.ECCO'24 Stockholm
Year: 2024
Authors: Saha, Kushal